



# ConvergeHEALTH Miner™ Access Suite

## State Price Transparency Solution



Deloitte's state price transparency solution, within ConvergeHEALTH's Miner Access suite, offers a platform to assist pharmaceutical manufacturers with complying with state price transparency reporting obligations.

### What is the Miner Access Suite?

The ConvergeHEALTH Miner™ Access Suite is an integrated and intuitive platform for overall pricing and reimbursement decision support at scale. It is a data science-driven, integrated platform that help organizations define and anticipate the impact of contracting and pricing relationships, enabling increased access and improved outcomes for patients.

### Key Benefits of State Price Transparency Solution:

**Alignment on State Price Transparency Reporting Requirements:** Auditable, reproducible, and version-controlled methodologies to determine triggers for all state price transparency reporting requirements that have been enacted

**Assist with Timely Reporting:** Accurately determine and track due dates of all reporting requirements to ensure timely submissions to each state

**Reduce Risk of Non-Compliance:** Assistance with regulatory and operational compliance requirements including full reproducibility, an audit trail, and analysis around reporting

**Operations are More Efficient and Effective:** As current states expand with requirements and new states are enacted, state price transparency resources can scale operations and do more in this area with less


**Integrated Pricing and Market Access Solution:** If used with Deloitte's other Miner Access Suite capabilities, overlapping data elements can create a decision support tool for pricing decision support

### Compliance with State Price Transparency Reporting

State price transparency reporting and notification requirements have been enacted across a myriad of states in response to widespread scrutiny on prescription drug costs. These laws complicate the regulatory landscape by requiring pharmaceutical manufacturers to provide sensitive product-specific financial information and file detailed reports with states regarding certain product launches and price increase decisions.

### Current states impacted:

As of 2021, there are *sixteen (16) states* that have approved and enacted regulations with potential reporting obligations: CA, CO, CT, LA, ME, MN, NH, NJ, NV, NY, OR, TX, UT, VT, WA and WV.



The reporting requirements can be specific to the following types: advance notice of price increases, price increase, periodic pricing, new drug entry, price disclosure to HCPs and states, and any newly acquired prescription drugs.

The Miner Access Suite is an intuitive platform that allows resources to house and stay informed on all current state price transparency laws while also having a mechanism to automate and track the compliance responsibilities associated with the state price transparency reporting requirements.

### State Price Transparency Solution: Capability Overview



**State Price Transparency dashboard:** A dashboard and user landing page with a map of enacted states and summary level information including tasks to be completed, calendar with upcoming due dates, reminder alerts, and other state-specific information



**Central repository of state price transparency information:** A central repository of state price transparency laws and interpretations, including ability to quickly view key information (e.g., description of requirement, effective date, report due date, etc.) and store supporting documentation



**Product and pricing information:** A repository of product (e.g., NDC, product name, launch date, etc.) and pricing information (e.g., WAC history) and qualitative information (e.g., marketing practices description) needed for trigger determination and reporting



**Rules engine:** Ability to configure state price transparency triggering rules and any pharmaceutical manufacturer interpretations to automate trigger determination process needed to identify if product requires reporting



**Report generation:** Ability to automatically generate applicable state price transparency reports with pre-populated information for each of the individual states as well as reporting types (e.g., Price increase notification and reporting) including reports in state defined formats



**Workflow management:** Ability to facilitate report approvals across stakeholders to enable consistent processes and an audit trail to track updates throughout the approval process



**Price scenario modeling:** Ability to assess the potential impact of future pricing decisions and inform leadership and other stakeholders of potential reporting obligations



**Analytics:** Ability to perform ongoing benchmarking and validations and confirm data is reported accurately and consistently

### Miner Access Suite capabilities

**Pricing Analytics:** Navigate and manage the intricacies of pricing adjustments regarding contractual agreements and compliance with state price transparency laws

**Value-based Analytics:** Streamlining the end-to-end process for administration of value-based agreements

#### Deal Analytics:

- **Pre-Deal Modeling:** Enhanced use of 3rd party data and AI techniques to enable robust predictive capabilities and meaningful benchmark to clarify business decisions related to managed care contracting decisions
- **Post-Deal Monitoring and Analytics:** Data driven analytics to understand the root cause of contract performance enabling real time market moves

## Start the conversation

If you are ready to explore how Deloitte's state price transparency solution can help you comply with state requirements and make your operations more efficient and effective, we should talk. For more information, please contact or visit:

<https://www2.deloitte.com/us/en/pages/consulting/solutions/convergehealthminer-lifecycle-management-pharma.html>

#### David Carlson

CS Managing Director  
Deloitte Consulting  
Deloitte & Touche LLP  
[dacarlson@deloitte.com](mailto:dacarlson@deloitte.com)  
+1 610 283 6273

#### Paul Silver

Principal  
Deloitte Risk and Financial Advisory  
Deloitte & Touche LLP  
[psilver@deloitte.com](mailto:psilver@deloitte.com)  
+1 404 229 8966

#### Clay Willis

Senior Manager  
Deloitte Risk and Financial Advisory  
Deloitte & Touche LLP  
[claywillis@deloitte.com](mailto:claywillis@deloitte.com)  
+1 404 825 3319

As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see [www.deloitte.com/us/about](http://www.deloitte.com/us/about) for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting. This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.